Accurately estimating kidney function is essential for the safe administration of renally cleared drugs such as ganciclovir. Current practice recommends adjusting renally eliminated drugs according to the Cockcroft-Gault equation. There are no data on the utility of the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations in ganciclovir dosing. To evaluate which renal function equation best predicts ganciclovir clearance.
Introduction
Ganciclovir, an acyclic nucleoside analogue of guanine, has proved effective in the prevention and treatment of cytomegalovirus disease in immunocompromised patients [1] . More than 90% of ganciclovir is eliminated, unchanged, in the urine. The ganciclovir clearance correlates well with glomerular filtration as estimated with creatinine clearance (CrCl) [2] . As a consequence, the pharmacokinetic parameters are markedly altered in patients with renal impairment if compared with the values obtained in patients with normal renal function [3, 4] . The recommended intravenous ganciclovir dose is 5 mg kg -1 , and this dosage should be adjusted to the renal status of each individual patient [5] . Accurately estimating kidney function is therefore essential for the optimal dosing of ganciclovir and as well as being highly recommended for drugs cleared by the kidney. For decades, calculating the estimated CrCl using the Cockcroft-Gault equation has been the most commonly used method for estimating kidney function for drugdosing purposes [6] . In the last few years, several new equations have been proposed. The Modification of Diet in Renal Disease (MDRD) Study equations and, more recently, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, provide an estimated glomerular filtration rate (GFR) and are widely used for staging chronic kidney disease [7] [8] [9] . Serum creatinine concentration is the key variable used in all of the equations. Historically, serum creatinine assays were not standardized, which contributed to significant interlaboratory variability in reported values. In an effort to solve this and improve the subsequent reliability of GFR results worldwide, the Creatinine Standardization Program was created [10] . As a result, essentially all clinical laboratories across the globe now report standardized serum creatinine values. Importantly, the original MDRD equation [4- variable MDRD Study (MDRD-4)] was re-expressed to use with standardized serum creatinine values [isotope dilution mass spectrometry (IDMS)-traceable 4-variable MDRD Study (MDRD4-IDMS) [11] . The Cockcroft-Gault equation cannot be re-expressed as the blood samples from the original study are no longer available. Consequently, when standardized serum creatinine values are used today with the Cockcroft-Gault equation, the estimated CrCl is systematically higher (typically 5-10%) than that observed before the implementation of standardized creatinine assays [12] . Due to the above, international regulatory agencies (the European Medicines Agency and Food and Drug Administration) and organizations [the National Kidney Disease Education Program (NKDEP) and Kidney Disease: Improving Global Outcomes (KDIGO)] are now working on improving pharmacokinetic studies with investigational drugs in patients with impaired renal function [13] [14] [15] [16] [17] . New studies aimed at updating current knowledge of approved drug dosage, in cases such as ganciclovir, should be promoted.
Presently, little is known about the use of these new equations as a descriptor for the pharmacokinetic profile and dose adjustment of renally excreted drugs [18] . It has not yet been established which equation best estimates ganciclovir clearance. The objective of the present study was to compare the renal function equations to discover which best estimates this clearance.
Methods

Study population
A retrospective study was performed using hospitalized adult patients treated with intravenous ganciclovir and available records of plasma drug levels from an 11-year period (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . Patients who received valganciclovir orally (prodrug of ganciclovir) and those who required renal replacement therapy were excluded. For each patient, the available data were age, sex, weight, height, serum creatinine levels and ganciclovir dosing history, including drug amounts, dosing time and blood sampling times. The peak and trough plasma levels of ganciclovir were systematically collected from patients' medical records. The current study was approved by the Ethics Committee of Vall d'Hebron Hospital and was carried out in accordance with the ICH Guidelines for Good Clinical Practice.
Therapeutic drug monitoring of ganciclovir
Monitoring plasma ganciclovir levels was only performed in some patients in our institution. The main clinical situations that led the doctor to monitor the drug were lack of efficacy, occurrence of serious adverse effects (for example neutropenia) or patients with impaired renal function. Samples of ganciclovir plasma levels were collected immediately before receiving the infusion to obtain the trough plasma level, and 1 hour after the administration to obtain the peak plasma level. Ganciclovir concentrations were measured by high-performance liquid chromatography with UV detection.
Renal function estimation
Renal function was estimated using the Cockcroft-Gault, MDRD4-IDMS and CKD-EPI equations for each patient. These three equations were selected because they are currently the most widely used for estimating renal function in clinical practice. The MDRD4-IDMS and CKD-EPI equations were also expressed in terms of individual body surface area (BSA), as recommended for drug dosing in small and large patients by the NKDEP [16] . The individual BSA was estimated by Mosteller formula [19] . These five equations are detailed in Table 1 
Study population groups
The patient population was divided into two groups: a learning group of the first three-quarters of the patients and a validation group comprising the remaining quarter. The learning group was used to assess the pharmacokinetic parameters and their relationship with the five equations for estimating renal function. The validation group established the goodness of fit of ganciclovir clearance according to the renal function estimation.
Pharmacokinetic analysis
The pharmacokinetic profile of ganciclovir is better explained by a two-compartment open model with constant intravenous input and first-order output as described previously [2, 4] .
Nevertheless, as only one peak and trough concentration per patient was available, the estimation of the individual pharmacokinetic parameters such as total plasma clearance (Cl, ml kg
), area under the plasma concentration-time curve (AUC, μg h ml
À1
) and terminal half-life (T ½ , h), was made by assuming a linear one-compartment model. A modification of the SawchuckZaske method [21] allowed the integration of the individual plasma ganciclovir concentration-time data from each patient, and population data of volume of distribution (Vd) [4] . Table 2 shows the calculation of ganciclovir clearance.
Table 1
Renal function estimation equations
White or other
MDRD4-IDMS and CKD-EPI adjusted to individual BSA (MDRD4-IDMS·BSA and CKD-EPI·BSA, respectively)
BSA, body surface area estimated by Mosteller equation [19] ; CrCl, creatinine clearance; GFR, glomerular filtration rate; SCr: serum creatinine Table 2 Calculation of ganciclovir clearance using a one-compartment model
2 Calculate the ganciclovir clearance (Cl, ml kg
Cl, total plasma clearance; C max , maximum (or peak) plasma concentration; C min , minimum (or trough) plasma concentration; K el , elimination constant rate; t max , time to maximum (or peak) plasma concentration; t min , time to minimum (or trough) plasma concentration; V d , volume of distribution. a Sommadossi et al. [4] studied the ganciclovir pharmacokinetic in 20 patients, 13 with normal renal function and 7 with renal impairment. They did not find differences between patients with normal renal function and patients with renal impairment (1.17 l kg -1 vs. 1.04 l kg -1 , respectively). Therefore, the average value of 1.12 l kg -1 for this sample of patients was used as the volume of distribution in our study.
Statistical analysis
In the learning group, a univariate linear regression model was used to compare the ganciclovir clearance assessed through ganciclovir serum concentrations using estimated GFR with the Cockcroft-Gault, MDRD4-IDMS, MDRD4-IDMS·BSA, CKD-EPI, or CKD-EPI·BSA equations. The coefficient of determination (R 2 ) was calculated to evaluate the predictive ability of each equation. Subgroup analysis was undertaken based on renal function (CKD-EPI < 90 ml min -1 1.73 m -2 ).
A univariate linear regression model was also used to compare the calculated ganciclovir clearance with the estimated ganciclovir clearance in the validation group. The calculated ganciclovir clearance was determined by the equation Cl = Kel·Vd. The estimated ganciclovir clearance was determined from the regression lines of the learning group for each renal function equations. The Bland-Altman analysis was used to describe agreement between the two quantitative measurements. Precision was calculated as root mean squared error (RMSE). Other statistical analysis performed included the paired samples t-test. A P value lower than 0.05 was required to achieve statistical significance.
The statistical analysis was conducted using the statistical package SPSS V.15.0 (SPSS Inc, USA).
Results
In total, 112 patients were selected. Of these, 100 met the inclusion criteria and were analysed. Three quarters of the patients (74) were treated between 2004 and 2012 and were analysed as the learning group. The other patients (26) were treated between 2013 and 2015 and were included in the validation group.
The characteristics of the entire study population are shown in Table 3 . The mean dose of ganciclovir was 4.4 mg kg -1 (286 mg). Seventy-one patients were administered ganciclovir twice a day; 27 patients received ganciclovir once a day; two patients were given it every 48 h. The estimated pharmacokinetic parameters values of ganciclovir are listed in Table 4 . The patient characteristics were comparable in the learning and validation groups.
In (Table 5) .
Regression analysis performed on a subgroup of 30 patients with impaired renal function (CKD-EPI <90 ml min 
Table 3
Characteristics of the 100 patients treated with intravenous ganciclovir [19] b Serum creatinine levels were determined when ganciclovir blood levels were monitored c The five equations showed significant correlation with each other, with a correlation coefficient of >0.8 (P < 0.001, in all cases).
The regression analysis between the calculated ganciclovir clearance and the estimated ganciclovir clearance showed a significant association with all renal function equations evaluated in the validation group (P < 0.05) ( Table 6 ). The t-test evidenced no differences between them. The BlandAltman graph plots using the five equations are depicted in Figure 1 . The Y axis shows the difference between the estimated ganciclovir clearance minus the measured ganciclovir clearance, ant the X axis represents the average of these measures. The mean bias is around 0 ml kg À1 min À1 and the 95% CI of limits of agreements are ± 2-3 ml kg À1 min À1 for all equations.
Discussion
Ganciclovir is a highly polar drug that is almost entirely excreted unchanged via glomerular filtration [2] . Equations that provide estimates of GFR can therefore be used to predict ganciclovir clearance and guide its dosing [2] . This is the first study to determine the equation that best predicts ganciclovir clearance. The Cockcroft-Gault and MDRD Study equations have been extensively studied and compared in different patient populations within the context of drug dosing, and recommendations vary with respect to which is best in patients with impaired kidney function [22] . Numerous published studies focus on the discordance between drug doses derived from the Cockcroft-Gault and MDRD Study equations, commonly reporting rates of between 10% and 40%, and speculate on the potential dangers of such differences (i.e. adverse patient outcomes) [12] . There are many important factors to be considered when assessing studies that compare the performance of the Cockcroft-Gault and MDRD Study equations for drug dosing. These factors include the weight used in the Cockcroft-Gault equation, the adjustment for BSA in the MDRD Study equation, the use of a standardized serum creatinine concentration, and the method used in the original pharmacokinetic studies from which the dosage recommendations for the drug under study were derived [12] . Table 5 Regression analysis and predictive ability of five renal function estimation equations for the elimination kinetics of ganciclovir in the learning group In all cases, P < 0.001
Park et al. [23] compared the Cockcroft-Gault and MDRD Study equations in 973 subjects and found that the CKD classification was similar (64.2%) with the two equations. Moreover, for 26 drugs that required renal dose adjustment, dose recommendations using MDRD were typically higher for subjects aged >80 years, weighing <55 kg, and with serum creatinine >0.7 and ≤1.5 mg dl -1 , compared with those from Cockcroft-Gault. Stevens et al. [24] compared CockcroftGault and MDRD-derived dosage recommendations for 15 renally eliminated drugs in a pooled analysis of 5504 participants. The authors reported that the Cockcroft-Gault equation was likely to assign patients to higher kidney function categories, resulting in higher dosage recommendations with this equation compared with MDRD. Drug-dose recommendations related to impaired GFR have historically been based on the Cockcroft-Gault equation [22] . However, it is also known that relatively few clinicians actually employ the Cockcroft-Gault equation for adjusting drug dose. Estimates of GFR have become more accessible to clinicians through the increasing availability of the automated reporting of these estimates, using the MDRD, and latterly the CKD-EPI, equations [25] . The CKD-EPI and MDRD4-IDMS equations were developed using IDMStraceable creatinine assays. The original Cockcroft-Gault equation was developed prior to this standardization, and there is no widely accepted modification of the equation in this setting. It is therefore important to address the performance of these equations in comparison to the CockcroftGault equation for drug dosing in an IDMS-traceable creatinine era.
Our findings contribute in three ways. Firstly, our study is the first to demonstrate the utility of the CKD-EPI equation for ganciclovir dosing in the setting of an IDMS-traceable creatinine assay; the CKD-EPI equation best estimates ganciclovir clearance. Furthermore, our learning group findings were fully reproduced in the validation group, with the CKD-EPI equation being undoubtedly the best predictor of ganciclovir clearance. Secondly, since the mean BSA of our study (1.76 m 2 ) is close to the normal value (1.73 m 2 ), neither the CKD-EPI·BSA nor the MDRD4-IDMS·BSA equations improve the estimation of ganciclovir clearance (30 and 31%, respectively). Finally, we have shown that the Cockcroft-Gault, MDRD4-IDMS·BSA, and CKD-EPI·BSA equations perform substantially worse below a GFR of 90 ml min -1 with respect to ganciclovir clearance, suggesting that these equations predict the clearance less well in patients with renal dysfunction. As the CKD-EPI equation is emerging as the preferred equation in clinical laboratories for estimating GFR, it is important to examine its performance in the drug-dosing setting, as ideally a single equation should be used for any scenario where a GFR estimate is required.
Data on the significance of the CKD-EPI equation in drug dosing are limited. Delanaye et al. [26] used a mathematical simulation to determine how patient characteristics (sex, age, weight, height and serum creatinine) influence discrepancies between the Cockcroft-Gault equation and the de-indexed CKD-EPI equations (in ml min -1 ), which are recommended for drug dosage adjustment. Among the variables analysed, age and weight were the most important and these systematically impacted the results of the equations. With increased age, the Cockcroft-Gault result became Table 6 Regression analysis and predictive ability between the calculated ganciclovir clearance and the estimated ganciclovir clearance in the validation group In all cases, P < 0.05
Figure 1
Plots of differences between the estimated ganciclovir clearance and calculated ganciclovir clearance versus the mean of the two measurements for the Cockcroft-Gault (A), MDRD4-IDMS (B), MDRD4-IDMS·BSA (C), CKD-EPI (D), and CKD-EPI·BSA (E), based on the 26-patient validation group. Legend: the centerline represents the difference mean and the end lines show the limits of agreements (±1.96·SD). GCl, ganciclovir clearance (ml kg À1 min À1 ); SD, standard deviation progressively lower than the result for CKD-EPI; when weight increased, the opposite occurred. Cartet-Farnier et al. [27] compared the estimates of renal function provided by the Cockcroft-Gault, MDRD Study and CKD-EPI equations in 249 elderly patients (mean age: 83.6 years), and concluded that the use of the MDRD and CKD-EPI equations compared with the Cockcroft-Gault equation was associated with dosage discrepancy in 20-25% of patients and 15% of drug orders, resulting in potential overdosing in 95% of cases.
As mentioned in the KDIGO guidelines [17] , most of these studies compared the equations with each other in hypothetical simulations and not with actual drug clearance. In our study, we compared the performance of the Cockcroft-Gault, MDRD4-IDMS and CKD-EPI equations against actual ganciclovir clearance. We are aware that there are earlier papers on this issue: Ryzner [28] found that aminoglycoside clearance correlated better with the Cockcroft-Gault equation using ideal body weight than with the MDRD4-IDMS equation in 55 patients; Pai et al. [29] demonstrated the utility of the CKD-EPI equation for predicting aminoglycoside clearance in a large cohort of 2073 cases. Charhon et al. [30] analysed 412 gentamicin concentrations from 92 geriatric patients and found that the predictive performance of the Cockcroft-Gault-based model was comparable to, or better than, that of the MDRD-based model at each stage of the analysis. Conil et al. [31] found that CKD-EPI was the best predictor of vancomycin clearance in 78 adult intensive care unit patients.
This study has several limitations that should be considered. Firstly, we only assessed three renal function estimation equations, while many others have been reported in the literature. We focused on the Cockcroft-Gault, MDRD4-IDMS and CKD-EPI equations because these are the three most widely used equations in clinical practice. In addition, they are recommended by international regulatory agencies and organizations, as specified above.
Estimating renal function with the MDRD4-IDMS·BSA and CKD-EPI·BSA equations requires individual height and weight measurements. A limitation of the retrospective design of this study is that the heights of 16 patients did not figure in their medical records. To calculate the BSA of these patients, average Spanish heights were used (men: 173.1 cm; women: 162.3 cm). This is a potential source of imprecision when estimating renal function with the MDRD4-IDMS·BSA and CKD-EPI·BSA equations. However, this consideration had no effect on the mean height in the study (n = 84, mean height 168.0 cm).
Finally, collecting data retrospectively implied having no direct control over when the ganciclovir peak and trough concentrations were obtained in relation to when the dose was given.
In conclusion, the results of our study showed that, compared with the Cockcroft-Gault and MDRD4-IDMS equations, the CKD-EPI equation correlated better with ganciclovir clearance. Nevertheless, differences between equations are scarce, with a little clinical influence. Therefore, these data are useful to support use of the CKD-EPI although further studies are needed to evaluate new dose recommendations for ganciclovir according to this equation.
